Development of a low dose clinical lung screening prototype for early detection of COPD and lung cancer using a novel x-ray source to enable Talbot-Lau interferometry

Information

  • Research Project
  • 10274731
  • ApplicationId
    10274731
  • Core Project Number
    R44HL154950
  • Full Project Number
    4R44HL154950-02
  • Serial Number
    154950
  • FOA Number
    PA-19-272
  • Sub Project Id
  • Project Start Date
    6/1/2021 - 3 years ago
  • Project End Date
    5/31/2023 - a year ago
  • Program Officer Name
    GAN, WEINIU
  • Budget Start Date
    6/1/2021 - 3 years ago
  • Budget End Date
    5/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    02
  • Suffix
  • Award Notice Date
    5/31/2021 - 3 years ago
Organizations

Development of a low dose clinical lung screening prototype for early detection of COPD and lung cancer using a novel x-ray source to enable Talbot-Lau interferometry

Project Summary/Abstract Chronic obstructive pulmonary disease (COPD) and lung cancer are the third and sixth most common causes of death worldwide. One major challenge is that there are no effective screening methods capable of early detection of these diseases and when these diseases are finally detected, they are often at advanced stages for which few effective treatment strategies exist. In the case of lung cancer, more than half of people die within the year of diagnosis. Darkfield (scattering-based) x-ray contrast has been recently demonstrated to provide exciting capabilities for early detection of lung pathologies, including cancer and COPD at doses comparable to conventional chest radiography. This contrast mechanism differs significantly from current approaches, which use the absorption of x-rays for contrast rather than the scattering of x-rays. Accessing information provided by this contrast mechanism requires an emerging grating-based x-ray technique called Talbot-Lau interferometry, which uses three sets of gratings (source, phase, and detector) to achieve contrast. However, a critical bottleneck for using this technique at the high x-ray energies (~60 keV) required for imaging through a human chest is a source grating with the aspect ratios required cannot be fabricated. We propose to develop a lung darkfield imaging prototype using a major x-ray source innovation that removes the need for the x-ray source grating to enable Talbot-Lau interferometry at high x-ray energies. The system will critically enable demonstrations of the clinical potential of darkfield radiography for early detection of lung pathologies. The proposed Phase I 6-month project is a proof-of-principle of a grating-less Talbot-Lau breadboard set-up on a phantom. The proposed Phase II 24-month project is to develop a complete prototype system and experimentally verify its performance.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R44
  • Administering IC
    HL
  • Application Type
    4
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    840685
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    838
  • Ed Inst. Type
  • Funding ICs
    NHLBI:840685\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SIGRAY, INC.
  • Organization Department
  • Organization DUNS
    079183051
  • Organization City
    CONCORD
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    945205345
  • Organization District
    UNITED STATES